Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Zhao, Xiaolianga; b; c | Wen, Xiaohuad | Wei, Weia; b; c | Su, Yanjuna; b; c | You, Jiana; b; c | Gong, Liquna; b; c | Zhang, Zhenfaa; b; c | Wang, Menga; b; c | Xiao, Jianyub; c; e | Wei, Xiyinc; f | Wang, Changlia; b; c; *
Affiliations: [a] Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China | [b] Tianjin Lung Cancer Center, Tianjin 300060, China | [c] Tianjin Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin 300060, China | [d] Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China | [e] Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China | [f] Public Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
Correspondence: [*] Corresponding author: Changli Wang, Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China. Tel.: +86 18622221060; Fax: +86 2223053070; E-mail: wangchangli@medmail.com.cn.
Abstract: BACKGROUND: Endostar (rh-endostatin) is a new recombinant human endostatin, which could inhibit cell proliferation, angiogenesis, and tumor growth. OBJECTIVE: To explore anti-angiogenesis short-term efficacy combined with neoadjuvant chemotherapy for stage IIIA (N2) non-small cell lung cancer (NSCLC), and identify the potential predictive factors. METHODS: We pathologically examined 26 patients diagnosed with stage IIIA (N2) NSCLC who received NP chemotherapy alone or combined with Endostar, respectively. RESULTS: Our results indicated that total clinical benefit rate (CBR) 87.5% and 64% (p= 0.76), respectively. The clinical benefit (CB) patients in the treatment group showed significant changes in endothelial progenitor cells (EPC), vascular endothelial growth factor (VEGF), blood flow (BF), permeability surface (PMS), and microvascular density (MVD) before and after treatment. Compared with CB patients in the control group, changes in EPC and MVD (only) before and after treatment were significant. The variation of EPC, PMS, and MVD before and after treatment in the treatment group showed positive correlation with tumor regression rate (TRR) and the variation of MVD, whereas those of EPC and PMS demonstrated positive correlations with variation of MVD before and after treatment. CONCLUSION: Our findings suggested that PMS and EPC may be used as a predictive factor for the short-term efficacy of the combined therapy in NSCLC.
Keywords: RH-endostatin, non-small cell lung cancer, predictor, circulating endothelial progenitor cells, perfusion imaging
DOI: 10.3233/CBM-170565
Journal: Cancer Biomarkers, vol. 21, no. 1, pp. 169-177, 2018
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl